CERo Therapeutics, Inc. Presents CER-1236 Data Supporting Use in AML at Global Cell & Gene Therapy Summit 2024

Core Insights - CERo Therapeutics is preparing for initial human trials of its lead compound CER-1236 targeting acute myeloid leukemia (AML) following IND clearance [1][4] - The company presented data at the Global Cell & Gene Therapy Summit 2024, highlighting the prevalence of TIM-4-L in AML and its potential as a target for engineered T cell therapy [2][3] Company Overview - CERo Therapeutics is focused on developing next-generation engineered T cell therapeutics for cancer treatment, utilizing a proprietary approach that combines innate and adaptive immunity [5] - The company aims to create Chimeric Engulfment Receptor T cells (CER-T) that can potentially treat both hematological malignancies and solid tumors, with clinical trials for CER-1236 anticipated to start in 2024 [5] Research Findings - The poster presented at the summit indicates that TIM-4-L is commonly expressed in various AML subsets but absent in healthy tissues, making it a viable therapeutic target [2] - CER-1236 demonstrated significant in vitro and in vivo cytotoxicity against TP53 mutant AML, with toxicity studies showing no adverse effects on healthy tissue even at high doses [2][3]